hcv product sale continu declin deterior overal growth tp
maintain sell rate downgrad
tp estim tp base
forward price-to-earnings multipl adjust ep
provid downsid potenti
expect top-lin revenu declin
respect
estim base follow factor declin
revenu earn lower hcv sale quarter
launch new product strong perform hiv
gilead revenu decreas
compar due lower sale hcv
product net incom declin y/i
non-gaap net incom declin
y/i ep declin
y/i non-gaap ep declin
y/i
hcv product sale quarter
declin due lower sale harvoni epclusa across
major market result increas competit
hiv product sale increas y/i
increas due continu strong uptak
genvoya odefsey rapid adopt biktarvi
biktarvi receiv market author european
commiss june biktarvi launch germani
smaller countri eu
compani namegilead scienc inc tickergildstock ratingsellunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth decemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
yescarta launch unit state octob
gener sale quarter
center certifi provid treatment
kite gilead compani hifibio therapeut
biotechnolog compani focus discoveri
therapeut antibodi singl cell screen
analysi announc compani enter
research collabor licens agreement develop
technolog support discoveri neoantigen-
reactiv cell receptor tcr potenti treatment
variou cancer includ solid tumor
precis bioscienc announc
compani enter strateg
collabor develop therapi target
vivo elimin hepat viru hbv
gilead expect net product sale rang
non-gaap effect tax
rate expect rang
current price-to-earnings
price-to-earnings trade averag price-to-earnings
decemb june due declin ep
expect forward price-to-earnings
recommend sell rate base
perform expect declin revenu
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend yield n/a pay-out dividend date dec ex-dividend date dec last split factor new per last split date jan inform gilead scienc inc decemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli decemb
cash short-term total defer incom prepaid current total current net properti plant equiti intang defer incom long-term total non-curr total short-term account tax accru defer current total current long-term defer tax defer revenuesminor long-term total non-curr total common addit paid-in retain accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli decemb
provid oper activ decreas period compar
due lower product sale higher tax payment
provid invest activ period compar cash
use invest activ chang cash provid use invest activ
due lower purchas market secur higher proce matur market
secur partial off-set lower proce sale market secur
use financ activ period compar cash
provid financ activ chang cash provid use financ
activ due repay senior unsecur note upon matur repay
term loan borrow connect acquisit kite higher repurchas common stock
depreci investment/asset impair defer incom stock base chang work account prepaid account accru incom tax work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt common stock common stock excess tax benefit stock base dividend financ net cash provid use financ effect exchang rate net chang begin end decemb
gilead earn revenu declin quarter due declin
total revenu decreas compar
total product revenu declin
compar decreas due lower
sale hcv product partial off-set increas sale hiv product
product sale unit state decreas
compar product sale europ decreas
compar
product sale locat decreas
compar
cog increas compar
increas due amort expens relat
intang asset acquir connect acquisit kite gross
margin decreas compar due
chang product mix
 expens increas compar
non-gaap expens increas
compar increas
due higher cost support growth busi follow
acquisit kite stock-bas compens expens associ
acquisit kite
sg expens increas compar
non-gaap sg expens increas
compar increas
due increas expens support growth busi follow
acquisit kite stock base compens expens associ
acquisit kite partial off-set lower bpd fee
decreas
compar
increas
compar
incom expens increas compar
increas due unreal gain chang
fair valu market equiti secur
interest expens compar
effect tax rate compar
decreas tax rate due reduct
corpor tax rate result enact tax cut job act
tax reform decemb partial off-set chang geograph
mix earn global intang low-tax incom
net incom declin compar
non-gaap net incom declin
compar
ep declin compar
non-gaap ep declin
compar
septemb gilead cash cash equival
market secur compar june
quarter gilead gener oper cash flow gilead
repaid princip amount senior unsecur note due septemb
paid cash dividend util stock
period total revenu decreas
compar product sale decreas
compar decreas
due lower sale hcv product
net incom declin
compar
declin
compar
period total product sale decreas
compar
period total product sale europ decreas
compar
period total product sale locat decreas
compar decreas
due lower sale japan
period cog increas
compar increas due amort expens
relat intang asset acquir connect acquisit
kite period gross margin decreas
compar
period total expens increas
compar increas due
higher cost support growth busi follow acquisit
kite stock-bas compens expens associ acquisit
kite up-front collabor payment relat collabor
agreement inc
period sg expens increas
compar increas due increas
expens support growth busi follow acquisit
kite stock base compens expens associ acquisit
kite partial off-set lower bpd fee
period incom expens net increas
compar
period effect tax rate decreas compar
locat
decreas
compar
period effect tax
rate decreas
compar
period ep decreas
compar
hcv product sale
consist epclusa harvoni
vosevi sovaldi
decreas
compar
period total incom decreas
compar period ep
decreas compar
gilead portfolio market product includ ambisom atripla
stribild truvada tybost vemlidi viread vosevi yescarta
gilead intern commerci sale oper market
subsidiari countri gilead also sell distribut certain
product corpor partner royalty-pay collabor
total product revenu declin compar
due lower sale hcv product
month period total product sale compar
product sale europ
locat
hcv product sale consist epclusa harvoni vosevi sovaldi
decreas compar
declin due lower sale harvoni epclusa sovaldi
across major market result increas competit
period hcv product sale decreas
compar due lower sale
harvoni epclusa sovaldi across major market result
epclusa sale declin compar
period epclusa sale declin
compar sale
epclusa decreas across major market due lower averag net sell
price result increas competit
epclusa sale declin
compar epclusa sale europ declin
compar epclusa
sale locat increas
compar
harvoni sale declin compar
period harvoni sale declin
compar decreas
major market due lower sale volum result increas
harvoni sale declin
compar harvoni sale europ declin
compar harvoni
sale locat declin
compar
product cayston hepsera sovaldi
product sale decreas compar
due lower sovaldi sale sale sovaldi decreas
compar due lower sale
volum led shift market sovaldi epclusa
epclusa sale declin
compar
harvoni sale declin
compar
increas
compar
descovi sale increas
compar
product cayston hepsera sovaldi
period product sale decreas
compar period sale
sovaldi decreas compar
hiv product sale increas compar
period hiv product sale
increas compar
hiv product sale increas due continu uptak descovi
genvoya odefsey launch biktarvi biktarvi approv
fda februari european commiss june
descovi ftc/taf -base product biktarvi descovi genvoya odefsey
product sale descovi ftc/taf -base product
compar period
sale compar
sale descovi ftc/taf -base product
europ increas major market
due higher sale volum reflect increas demand
descovi genvoya odefsey launch biktarvi
descovi sale increas compar
period descovi sale increas
compar
biktarvi sale
month period
odefsey sale increas
compar
product sale
product
compar
descovi ftc/taf -base product biktarvi descovi genvoya
genvoya sale increas compar
period genvoya sale increas
compar
odefsey sale increas compar
period odefsey sale increas
compar
truvada ftc/tdf -base product atripla complera/eviplera stribild
product sale truvada ftc/tdf -base product
compar period
total product sale compar
sale truvada ftc/tdf -base product
unit state europ locat
unit state decreas due lower sale volum result
continu uptak descovi ftc/taf -base product partial
off-set increas usag truvada prep higher averag net
europ decreas due lower sale volum result
avail gener version truvada atripla continu
uptak descovi ftc/taf -base product
atripla sale declin compar
period total sale declin
compar
complera/eviplera sale declin
compar period total sale
declin compar
truvada ftc/tdf -base product atripla complera/eviplera stribild
stribild sale declin
compar
stribild sale declin compar
period total sale declin
compar
truvada sale declin compar
period total sale declin
compar
product sale includ product hbv cardiovascular
oncolog categori inclus vemlidi viread letairi ranexa
zydelig ambisom decreas
compar period sale
declin compar
sale viread decreas due avail gener version
letairi expect face gener competit unit state
 patent ambrisentan activ pharmaceut
ingredi letairi expir juli ranexa expect face
gener competit unit state start
yescarta launch unit state octob
gener sale yescarta gener sale
period
yescarta
launch unit
state octob
gener sale
product pipelin updat
product pipelin updat announc gilead
hiv liver diseas program
announc strateg collabor precis bioscienc
precis develop therapi target vivo elimin hbv
viru precis proprietari genom edit platform arcu
announc china nation drug administr approv
genvoya treatment infect
present data aid confer includ
announc retrospect nationwid analysi impact
truvada pre-exposur prophylaxi prep use across state
district columbia
conduct collabor research emori univers rollin
school public health center diseas control prevent
data demonstr use once-daili oral truvada prep
independ signific impact number new hiv
infect diagnos unit state
oncolog cell therapi program
announc licens agreement trianni inc trianni grant
gilead use trianni transgen human monoclon antibodi
discoveri platform support drug discoveri effort
announc european commiss grant market
author yescarta treatment adult patient relaps
refractori diffus larg b-cell lymphoma primari mediastin larg b-
cell lymphoma two line system therapi
announc strateg collabor gadeta gadeta
develop novel gamma delta cell receptor therapi variou cancer
collabor
precis develop
therapi target
vivo elimin hbv
viru precis
collabor gadeta
 gadeta develop
receptor therapi
biktarvi approv
eu june
launch
product pipelin updat
product pipelin updat announc gilead
announc finch global random placebo-control phase
studi filgotinib investig select inhibitor adult
moderately-to-sever activ rheumatoid arthriti prior inadequ
response/intoler biolog agent achiev primari endpoint
proport patient achiev american colleg rheumatolog
respons week
announc random placebo-control phase tortuga
studi filgotinib achiev primari efficaci endpoint adult
moder sever activ ankylos spondyl studi
patient treat filgotinib achiev significantli greater improv
diseas activ score primari endpoint week mean
chang baselin versu treat placebo
pipelin mileston anticip
endpoint data phase
studi prep
biktarvi approv eu june launch
vesatolimod complet phase studi hiv cure
capsid inhibitor initi phase studi
gs- data phase studi
descovi primari endpoint data phase studi prep
product pipelin updat
pipelin mileston anticip
nash pbc psc
data phase nash
psc data
phase pbc
data stellar phase studi nash
data stellar phase studi nash
data phase nash psc
data phase pbc
data atla phase studi selonsertib and/or
and/or patient advanc fibrosi due nash
complet equat phase studi psoriat arthriti
complet tortuga phase studi ankylos spondyl
data finch phase studi ra
data finch phase studi ra
data finch phase studi ra
complet enrol select phase studi uc
complet enrol divers phase studi crohn diseas
data phase studi cutan lupu erythematosu
data phase studi sjogren syndrom
data phase
studi cutan lupu
erythematosu
data phase studi
sjogren syndrom
adult
initi phase
pediatr
enrol phase
product pipelin updat
pipelin mileston anticip
complet phase studi ebola survivor
approv eu aggress nhl
complet enrol phase combo
follow data
complet enrol phase indol nhl
complet enrol phase line dlbcl
initi phase combo
initi phase adult
initi phase pediatr
complet enrol phase mcl
initi phase cll
complet enrol phase studi anti-bcma mm
decis registr studi base phase data
complet enrol phase mage solid tumor
file ind tcr target solid tumor
achiev first endpoint phase combin studi r/r cll
tabl show pipelin product candid gilead
tabl show pipelin product candid gilead
trialind areaiiiiiihematology/oncologyaxicabtagen nhldlbcl allpediatr mage tumorentospletinib inhibitor heme malignanciestirabrutinib btk inhibitor b-cell malignanciesphas gilead scienc
announc
compani enter
strateg
collabor develop
therapi target
vivo elimin
precis
guidanc conclus
expect net product sale
non-gaap tax rate expect rang
gilead revenu decreas compar
due lower sale hcv product net incom declin
y/i ep declin
y/i non-gaap ep declin y/i
hcv product sale decreas y/i declin
due lower sale harvoni epclusa sovaldi across major
market result increas competit
hiv product sale increas y/i hiv product
sale increas due continu uptak descovi genvoya odefsey
launch biktarvi biktarvi approv fda februari
european commiss june
yescarta launch unit state octob gener
sale quarter center certifi
provid treatment yescarta
precis bioscienc announc compani
enter strateg collabor develop therapi target
vivo elimin hepat viru hbv precis proprietari
non- reconcili
non- reconcili
non- reconcili
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin decreas ttm compar due increas cog
oper margin declin ttm compar due increas expens
ep growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth gilead scienc inc decemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale gilead scienc inc decemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset gilead scienc inc decemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item gilead scienc inc decemb
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas business- sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free decemb
current price-to-earnings price-to-earnings trade averag price-to-earnings
decemb june due declin ep expect
forward price-to-earnings
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc capit research global fmr parnassu invest northern trust price row associ top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard invest compani spdr etf vanguard institut fund-institut etf tr- qqq tr seri parnassu equiti ishar nasdaq biotechnolog growth fund america dodg cox stock decemb
developmentschina nation medic product administr nmpa approv gilead vemlidi tenofovir alafenamid chronic hepat viru hbv infectionnovemb scienc inc announc thechina nation medic product administr nmpa approv vemlidi tenofovir alafenamid taf mg once-daili treatment chronic hepat adult adolesc age older bodi weight least scienc tango announc strateg collabor develop next-gener immuno-oncolog therapiesoctob scienc inc andtango inc compani focus discoveri develop novel cancer therapi announc global strateg collabor discov develop commerci pipelin innov target immuno-oncolog treatment patient cancer kite hifibio announc research collabor develop technolog potenti discoveri neoantigen-react cell receptor tcr treatment canceroctob agilead compani hifibio biotechnolog compani focus discoveri therapeut antibodi singl cell screen analysi announc compani enter research collabor licens agreement develop technolog support discoveri neoantigen-react cell receptor tcr potenti treatment variou cancer includ solid tumor gilead scienc precis bioscienc announc collabor develop therapi hepat viru use genom editingseptemb sciencesand precis bioscienc announc compani enter strateg collabor develop therapi target vivo elimin hepat viru hbv precis proprietari genom edit platform decemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit gilead scienc inc decemb
consensu view analyst trend stock
compar
forward price-to-earnings
compar
 average
annual usdgrowth high day day day estim avgfive-year growth forecast comparisongildindustri avg avgprice/earn yield decemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last daysn/an/an/an/aup last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr decemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show huge fluctuat quarter dip novemb
averag daili volum share trade quarter gave neg
return period
stock price volatil year gave return year
rang stock
stock price trade decemb later declin due lower sale hcv
stock current trade given neg return past
gilead revenu declin due lower product sale hcv product
saw strong perform hiv product yescarta biktarvi saw strong growth sinc launch
expect see growth futur well recommend sell rate tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
